ArticleBMC neurology2025
The effect of remote ischemic conditioning combined with tirofiban on early neurological deterioration in small artery occlusive stroke.
Article in BMC neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Article
- Efficacy and safety of treatment strategies for early neurological deterioration after acute ischemic stroke: a network meta-analysis of randomized controlled trials.BMC neurology · 2026Article
- Effect of remote ischemic preconditioning on the risk of contrast-induced acute kidney injury in patients with coronary heart disease undergoing percutaneous coronary intervention.Frontiers in cardiovascular medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesEarly neurological deterioration (END) remains a significant challenge in the treatment of small artery occlusive (SAO) stroke. The purpose of this study was to evaluate the efficacy and safety of remote ischemic conditioning (RIC) combined with tirofiban for patients with SAO stroke experiencing END.
methodsWe retrospectively reviewed 143 consecutive patients with acute SAO stroke experiencing END who received intravenous tirofiban between January 2021 and December 2024. According to the use of RIC treatment, the patients were divided into RIC group (72 cases) and control (no-RIC) group (71 cases). The primary efficacy outcome was early neurological improvement (a decrease of ≥2 points in the National Institutes of Health Stroke Scale (NIHSS) score at 7 days after END). The secondary efficacy outcomes included absolute reduction in NIHSS score at 7 days, modified Rankin Scale scores at 90 days, proportion of disabling stroke, recurrence of ischemic stroke within 90 days. The safety outcomes were symptomatic intracranial hemorrhage, any ICH, adverse events, and 90-day all-cause mortality.
resultsThe RIC group exhibited a greater absolute reduction in NIHSS score at 7 days after treatment (mean ± SD: 1.67 ± 1.80 vs. 0.96 ± 1.91; adjusted P=0.015), and early neurological improvement was achieved in 55.6% of the RIC group and 29.6% of the control group (adjusted odds ratio, 3.34 [95% CI, 1.61-6.93]; P=0.001). No symptomatic intracranial hemorrhage or any intracranial hemorrhage occurred in either group. Additionally, the 90-day all-cause mortality did not differ significantly between the RIC and sham groups (1.4% vs. 2.8%, hazard ratio, 0.49 [95% CI, 0.04-5.41]; P=0.561).
conclusionsIn patients with small artery occlusive stroke experiencing END, the combination of RIC and tirofiban seems associated with early neurological improvement without increasing the risk of intracranial hemorrhage or serious adverse events. Future multicenter, large-sample randomized clinical trials are warranted to validate these results.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.